Demand for protein drug candidates is surging. Hundreds of antibodies are in clinical and preclinical studies. From 2005 to the middle of 2006, large biopharmaceutical companies have spent or pledged over $4 billion to acquire firms developing monoclonal antibodies. But despite swelling pipelines, protein candidates face a bottleneck that stretches from in vitro testing all the way to proof-of-concept clinical trials. The time required to produce enough protein for these stages can add as much as a year to the drug development process, along with concomitant expenses, and the unpredictability of cell line development complicates strategic planning.
Selexis’ innovative technology has been designed to address these critical factors by combining an unprecedented speed in engineering stable cell lines with high cell productivity levels.
Selexis’ technology drastically decreases the overall costs in recombinant protein drug development and manufacturing.
Because the Selexis’ technology is based on industry-standard processes for generating cell lines, it is easily and efficiently implemented into the partner’s hands.
